5 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 13,082 as of Monday, Nov. 5, 2012, 1:34 PM ET. The NYSE advances/declines ratio sits at 1,351 issues advancing vs. 1,574 declining with 129 unchanged.

The Drugs industry currently sits up 1.1% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Pharmacyclics Incorporated ( PCYC), up 10.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Endo Health Solutions ( ENDP) is one of the companies pushing the Drugs industry lower today. As of noon trading, Endo Health Solutions is down $2.22 (-7.6%) to $27.01 on heavy volume Thus far, 4.0 million shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $26.81-$29.22 after having opened the day at $29.09 as compared to the previous trading day's close of $29.23.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $3.4 billion and is part of the health care sector. The company has a P/E ratio of -967.0, below the S&P 500 P/E ratio of 17.7. Shares are down 16.0% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Endo Health Solutions a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Endo Health Solutions Ratings Report now.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds